Avanos Medical, Inc.
11.43-0.15 (-1.3%)
Oct 29, 4:00:02 PM EDT · NYSE · AVNS · USD
Key Stats
Market Cap
530.38MP/E (TTM)
-Basic EPS (TTM)
-10.02Dividend Yield
0%Recent Filings
8-K
Avanos cuts executive roles
Avanos Medical eliminated its Chief Commercial Officer and General Counsel positions on October 21, 2025, effective December 1, 2025, as part of a broader restructuring. Responsibilities shift to other employees, with Kerr Holbrook and Mojirade James receiving severance of $1,535,417 and $1,425,665, respectively, plus 12 months of COBRA premiums and prorated 2025 bonuses at target. Unvested equity vests pro rata for time-based units and based on performance for others. Restructuring streamlines operations but signals internal shifts.
8-K
Avanos acquires Nexus Medical
Avanos Medical acquired Nexus Medical on September 15, 2025, adding the proprietary TKO anti-reflux needleless connector to bolster safer nutrition and medication delivery in NICUs and PICUs. This complements Avanos' Specialty Nutrition Systems, extending its strategy for reliable critical care solutions. The deal, financed with cash, proves immediately accretive to revenue and earnings. Yet integration risks linger undisclosed.
8-K
Q2 sales rise, HA divestiture
Avanos Medical reported Q2 2025 net sales of $175.0 million, up 1.9% year-over-year, driven by 5.1% growth in Specialty Nutrition Systems yet offset by a $77.0 million goodwill impairment in Pain Management & Recovery, swinging to a $76.8 million net loss. The company divested its Hyaluronic Acid line to Channel-Markers Medical on July 31, 2025, to sharpen focus on core segments. It appointed Scott Galovan as CFO effective August 1, with a $460,000 base salary and $500,000 equity inducement. Leadership stabilizes amid transformation.
10-Q
Q2 FY2025 results
Avanos Medical posted Q2 net sales of $175.0 million, up 1.9% year-over-year, with Specialty Nutrition Systems driving 5.1% growth to $102.7 million on strong enteral feeding and neonate demand, while Pain Management and Recovery edged up 2.9% to $61.0 million thanks to 13.7% radiofrequency ablation gains offsetting surgical pain declines. Gross margin slipped to 52.6% from 55.7%, pressured by higher tariffs and costs, yet operating loss of $74.5 million stemmed mainly from a $77.0 million goodwill impairment in the PM&R unit triggered by market cap drops. Cash from operations hit $32.5 million for the half-year, funding $17.7 million capex and $29.7 million debt paydown to $105.1 million total, leaving $90.3 million in cash and full revolver availability under 2027 maturities. Free cash flow stood at $14.8 million (derived). Diluted EPS loss of $(1.66) aligned with 46.3 million shares. Post-quarter, the HA assets sale sharpens focus on core segments. Tariffs on Mexico-sourced goods pose supply chain risks.
8-K
Q1 sales up 0.8%, EPS guidance cut
Avanos Medical reported Q1 2025 net sales of $167.5 million, up 0.8% year-over-year, with organic growth of 2.8% after adjustments. The Specialty Nutrition Systems segment surged 6.9% to $101.1 million on 8.7% volume gains, while Pain Management and Recovery held flat at $56.2 million, boosted by 8.2% radiofrequency ablation growth yet dragged by 9.3% surgical pain declines. Net income climbed to $6.6 million from $0.5 million; the company holds 2025 revenue guidance at $665–$685 million but trimmed adjusted EPS to $0.75–$0.95 due to tariff pressures. Tariffs pose material risks if mitigation falters.
AORT
Artivion, Inc.
44.99-0.27
AVAH
Aveanna Healthcare Holdings Inc
9.86+0.05
BVS
Bioventus Inc.
6.77-0.17
CV
CapsoVision, Inc.
4.67-0.01
ENOV
Enovis Corporation
31.99-0.87
NAOV
NanoVibronix, Inc.
5.57-0.32
NUWE
Nuwellis, Inc.
3.05-0.05
NVNO
enVVeno Medical Corporation
0.72+0.00
PAVM
PAVmed Inc.
0.44+0.00
SNWV
SANUWAVE Health, Inc.
30.44-0.60